Skip to main content

IO Biotech, Inc.

IOBTDelisted Jun 8, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001865494

IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.

Q2 2022 vs. Q1 2022

How the institutions holding IO Biotech, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of IOBT: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders1918−1
Shares14.9M15.5M+594.7K (+4.0%)
Value$76.9M$72.2M−$4.70M (−6.1%)

New holders (5)

Institutions that held IO Biotech, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to IOBT in Q2 2022
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC75,000$350.0K0.01%
Citadel Advisors LLC14,426$67.0K0.00%
Cannell Capital LLC2,192$10.0K0.00%
UBS Group AG2,234$10.0K0.00%
Tower Research Capital LLC (TRC)524$2.00K0.00%

Sold out (6)

Institutions that held IO Biotech, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of IOBT in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Vanguard Group Inc62,234$330.0K
Susquehanna International Group, LLP26,676$141.0K
Norges Bank25,000$132.5K
Jane Street Group, LLC14,280$76.0K
Ergoteles LLC11,126$59.0K
Stifel Financial Corp10,000$53.0K